Goodwill and Intangible Assets	3 Months Ended
Mar. 31, 2020
Goodwill and Intangible Assets
Goodwill and Intangible Assets	Note 6 — Goodwill and Intangible Assets The total amount of goodwill reported was $22.9 billion at March 31, 2020 and $23.2 billion at December 31, 2019. Foreign currency translation adjustments decreased goodwill by approximately $268 million in the first three months of 2020. The amount of goodwill related to reportable segments at March 31, 2020 was $2.8 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.6 billion for the Diagnostic Products segment, and $16.1 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first three months of 2020. The gross amount of amortizable intangible assets, primarily product rights and technology was $27.3 billion as of March 31, 2020 and $27.6 billion as of December 31, 2019, and accumulated amortization was $12.3 billion as of March 31, 2020 and $11.9 billion as of December 31, 2019. Foreign currency translation adjustments decreased intangible assets by $204 million for the first three months of 2020. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2020, $2.0 billion in 2021, 2022, and 2023 and $1.9 billion in 2024. Indefinite-lived intangible assets, which relate to in-process R&D acquired in a business combination, were approximately $1.2 billion and $1.3 billion as of March 31, 2020 and December 31, 2019, respectively.

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2020

Note 6 — Goodwill and Intangible Assets

The total amount of goodwill reported was $22.9 billion at March 31, 2020 and $23.2 billion at December 31, 2019. Foreign currency translation adjustments decreased goodwill by approximately $268 million in the first three months of 2020. The amount of goodwill related to reportable segments at March 31, 2020 was $2.8 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.6 billion for the Diagnostic Products segment, and $16.1 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first three months of 2020.

The gross amount of amortizable intangible assets, primarily product rights and technology was $27.3 billion as of March 31, 2020 and $27.6 billion as of December 31, 2019, and accumulated amortization was $12.3 billion as of March 31, 2020 and $11.9 billion as of December 31, 2019. Foreign currency translation adjustments decreased intangible assets by $204 million for the first three months of 2020. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2020, $2.0 billion in 2021, 2022, and 2023 and $1.9 billion in 2024.

Indefinite-lived intangible assets, which relate to in-process R&D acquired in a business combination, were approximately $1.2 billion and $1.3 billion as of March 31, 2020 and December 31, 2019, respectively.